Another epilepsy drug may work for headaches

July 5, 2010

Many, but not all epilepsy drugs are also effective in preventing migraine headaches. For example, divalproex sodium (Depakote), topiramate (Topamax), and to a lesser degree gabapentin (Neurontin), pregabalin (Lyrica), and levetiracetam (Keppra) relieve migraine headaches, while other epilepsy drugs, such as phenytoin (Dilantin) and carbamazepine (Tegretol) do not. A report by Drs. Krusz at the annual meeting of the American Headache Society held last month suggests that a new epilepsy drug, lacosamide (Vimpat) may also be effective for the treatment of headaches. Dr. Krusz treated 22 patients with chronic migraines (patients who had more than 15 headache days each month) with this medication and discovered that on average the monthly number of headaches dropped from 21 to 13.  Side effects, such as drowsiness, nausea, and cognitive impairment lead 4 patients to stop the drug. Despite very impressive results it is premature to declare lacosamide an effective headache treatment because the study was very small and not placebo-controlled.

Written by
Alexander Mauskop, MD
Continue reading
September 7, 2025
How Artificial Sweeteners May Be Affecting Your Brain
A large Brazilian study published in Neurology followed nearly 13,000 adults for eight years and found something troubling: people who consumed the most artificial sweeteners showed faster cognitive...
Read article
August 30, 2025
Lithium Levels are low in Alzheimer’s. Is there a role in Migraine and Chronic Pain?
Recently published research on lithium deficiency in Alzheimer’s disease has caught the attention of the media. As a neurologist specializing in pain and headache medicine with an interest in no...
Read article
August 16, 2025
The Healing Power of Holding Hands: Insights from Neuroscience on Pain Relief
There’s something powerful about human touch when you’re hurting. As a neurologist, I see every day how a gentle hand squeeze from someone you trust can shift your pain—not just emotionally, but in...
Read article